Jathal, Maitreyee K.
Steele, Thomas M.
Siddiqui, Salma
Mooso, Benjamin A.
D’Abronzo, Leandro S.
Drake, Christiana M.
Whang, Young E.
Ghosh, Paramita M.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01CA185509)
U.S. Department of Veterans Affairs (I01BX000400)
Article History
Received: 10 February 2019
Revised: 14 May 2019
Accepted: 24 May 2019
First Online: 18 June 2019
Competing interests
: The authors declare no competing interests.
: De-identified human sera from a previously reported trial<sup>20</sup> were used in these studies. At the time of collection, the study was approved by an Institutional Review Board at the University of North Carolina Chapel Hill, NC and all patients gave written informed consent. The study had been registered with clinicaltrials.gov, number NCT00246753 and was performed in accordance with the Declaration of Helsinki. Mice were used in accordance with University of California Davis IACUC protocol number 15753. Only male mice were used since the study aimed to identify mechanisms of prostate cancer, which is a male-specific disease.
: This work was supported by a Biomedical Laboratory Research & Development (BLRD) service Merit Award (I01BX000400, PMG) from the Department of Veterans Affairs and by Award R01CA185509 (PMG) from the National Institutes of Health.
: All data generated or analysed during this study are included in this published article [and its supplementary information files]. Additional data and methods are described in Supplementary information available at the British Journal of Cancer’s website
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).